References
- Brouwer KL , KepplerD, HoffmasterKAet al. In vitro methods to support transporter evaluation in drug discovery and development. Clin. Pharmacol. Ther.94 (1), 95–112 (2013).
- Foti RS , WienkersLC, WahlstromJL. Application of cytochrome P450 drug interaction screening in drug discovery. Comb. Chem. High Throughput Screen.13 (2), 145–158 (2010).
- Honma M , KozawaM, SuzukiH. Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems. Expert Opin. Drug Discov.5 (5), 491–511 (2010).
- Volpe DA . Transport assays as useful in vitro tools in drug development. Expert Opin. Drug Discov.11 (1), 91–103 (2016).
- Zientek MA , YoudimK. Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes. Drug Metab. Dispos.43 (1), 163–181 (2015).
- US FDA . Guidance for Industry. In Vitro Metabolism- and Transporter- Mediated Drug–Drug Interaction Studies. (2017). www.fda.gov/downloads/drugs/guidances/ucm292362.pdf
- European Medicines Agency . Guideline on the Investigation of Drug Interactions (2012). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf
- Kim RB . Transporters and drug discovery: why, when, and how. Mol. Pharm.3 (1), 26–32 (2006).
- Zhang L , ZhangYD, ZhaoP, HuangSM. Predicting drug–drug interactions: an FDA perspective. AAPS J.11 (2), 300–306 (2009).
- US FDA Guidance for Industry. Clinical Drug Interaction Studies - Study Design, Data Analysis, and Clinical Implications (2017). www.fda.gov/downloads/drugs/guidances/ucm292362.pdf
- Fowler S , ZhangH. In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug–drug interactions. AAPS J.10 (2), 410–424 (2008).
- Walsky RL , ObachRS. Validated assays for human cytochrome P450 activities. Drug Metab. Dispos.32 (6), 647–660 (2004).
- Spaggiari D , GeiserL, DaaliY, RudazS. A cocktail approach for assessing the in vitro activity of human cytochrome P450s: an overview of current methodologies. J. Pharm. Biomed. Anal.101, 221–237 (2014).
- Zambon S , FontanaS, KajbafM. Evaluation of cytochrome P450 inhibition assays using human liver microsomes by a cassette analysis/LC-MS/MS. Drug Metab. Lett.4 (3), 120–128 (2010).
- Perloff ES , MasonAK, DehalSSet al. Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica39 (2), 99–112 (2009).
- Venkatakrishnan K , ObachRS. Drug–drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr. Drug Metab.8 (5), 449–462 (2007).
- US FDA . Guidance for Industry. Bioanalytical Method Validation (2013). www.fda.gov/downloads/drugs/guidances/ucm368107.pdf
- Yao M , ZhuM, SinzMWet al. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC–MS/MS analysis. J. Pharm. Biomed. Anal.44 (1), 211–223 (2007).
- Wu X , WangJ, TanLet al. In vitro ADME profiling using high-throughput RapidFire mass spectrometry: cytochrome p450 inhibition and metabolic stability assays. J. Biomol. Screen.17 (6), 761–772, (2012).
- Cece-Esencan EN , FontaineF, PlasenciaGet al. Software-aided cytochrome P450 reaction phenotyping and kinetic analysis in early drug discovery. Rapid Commun. Mass Spectrom.30 (2), 301–310 (2016).